Search results for "skeletal"

showing 10 items of 3025 documents

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized t…

2019

Highlights • Hormonal receptors positive breast tumor and prostate cancer are managed with endocrine therapies. • Endocrine therapies designed for breast and prostate cancer are often associated to serious adverse skeletal related events, such fractures. • Denosumab is a monoclonal anti-body binding RANKL which acts as inhibitor of osteoclasts activity, thus increasing bone mass. • Denosumab was showed to strongly prevent hormonal therapies-related skeletal issues. • Denosumab administration results safe in bone mass increase and reduction of fractures risk.

0301 basic medicineOncologyRCTs randomized clinical trialrandomized clinical trialslcsh:Diseases of the musculoskeletal systemSettore MED/06 - Oncologia MedicaOsteoporosisBMD bone mass densityReview Articleandrogen deprivation therapyADTlaw.inventionAndrogen deprivation therapyProstate cancerhazard ratio0302 clinical medicineRandomized controlled triallawHRMedicineBreastSAEsCancerProstateRANKLCIMD mean differencelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRCTs randomized clinical trialsDenosumabOncology030220 oncology & carcinogenesisSAEs serious adverse eventsDenosumabmean differencemedicine.drugmedicine.medical_specialtylcsh:RC254-28203 medical and health sciencesBreast cancerRANKL receptor activator of nuclear factor-kB ligandBMDInternal medicineAdverse effectADT androgen deprivation therapyRCTsbusiness.industryMDmedicine.diseaseHR hazard ratioHormonereceptor activator of nuclear factor-kB ligandDiscontinuationCI confidence interval030104 developmental biologyFractureconfidence intervalADT androgen deprivation therapy; BMD bone mass density; Breast; CI confidence interval; Cancer; Denosumab; Fracture; HR hazard ratio; Hormone; MD mean difference; Prostate; RANKL receptor activator of nuclear factor-kB ligand; RCTs randomized clinical trials; SAEs serious adverse eventsserious adverse eventsbone mass densitylcsh:RC925-935businessJournal of Bone Oncology
researchProduct

Expansion of permanent first molars with rapid maxillary expansion appliance anchored on primary second molars

2018

Background To evaluate how the amount of expansion of the primary second molars, the patient's age, and the skeletal maturation stage influence the amount of expansion at the level of the permanent first molars. Material and methods Fifty-five patients aged between 6 and 11 years with a cervical vertebral maturation stage of CS1 or CS2 were retrospectively selected. The intermolar width was measured before and after expansion to evaluate the amount of expansion achieved at the level of the primary second molars and the permanent first molars. Stepwise multiple linear regression was used to evaluate how the amount of primary molars expansion, the patient's age, and the cervical vertebral mat…

0301 basic medicineOrthodonticsMolarbusiness.industryResearchTransverse maxillary deficiencyOrthodontics030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Maxillary expansionTransversal deficiencyMandibular second molar03 medical and health sciences030104 developmental biology0302 clinical medicineSkeletal maturationstomatognathic systemMaxillary expansion; Primary molars; Transversal deficiency; Dentistry (all)UNESCO::CIENCIAS MÉDICASPrimary molarsDentistry (all)MedicinebusinessGeneral DentistryRapid maxillary expansion appliance
researchProduct

Cytoplasmic body myopathy revisited.

2018

0301 basic medicinePathologymedicine.medical_specialtyCytoplasmic bodybusiness.industrymedicine.diseaseCongenital myopathy03 medical and health sciences030104 developmental biology0302 clinical medicineNeurologySkeletal pathologyMuscular DiseasesPediatrics Perinatology and Child HealthMutation (genetic algorithm)MutationmedicineHumansNeurology (clinical)medicine.symptomMyopathybusinessMuscle Skeletal030217 neurology & neurosurgeryGenetics (clinical)Neuromuscular disorders : NMD
researchProduct

Autophagic vacuolar myopathy is a common feature of CLN3 disease

2018

Abstract Objective The neuronal ceroid lipofuscinoses (NCL) are genetic degenerative disorders of brain and retina. NCL with juvenile onset (JNCL) is genetically heterogeneous but most frequently caused by mutations of CLN3. Classical juvenile CLN3 includes a rare protracted form, which has previously been linked to autophagic vacuolar myopathy (AVM). Our study investigates the association of AVM with classic, non‐protracted CLN3. Methods Evaluation of skeletal muscle biopsies from three, non‐related patients with classic, non‐protracted and one patient with protracted CLN3 disease by histology, immunohistochemistry, electron microscopy, and Sanger sequencing of the coding region of the CLN…

0301 basic medicinePathologymedicine.medical_specialtyDegenerative Disordermedicine.disease_cause03 medical and health sciencessymbols.namesake0302 clinical medicineMedicineResearch ArticlesSanger sequencingMutationbusiness.industryGenetic heterogeneityGeneral NeuroscienceSkeletal muscleHistology030104 developmental biologymedicine.anatomical_structureCLN3symbolsImmunohistochemistryNeurology (clinical)business030217 neurology & neurosurgeryResearch ArticleAnnals of Clinical and Translational Neurology
researchProduct

Autoimmune polyglandular diseases.

2019

Autoimmune polyglandular diseases (APD) are defined as the presence of two autoimmune -induced endocrine failures. With respect to the significant morbidity and potential mortality of APD, the diagnostic objective is to detect APD at an early stage, with the advantage of less frequent complications, effective therapy and better prognosis. This requires that patients at risk be regularly screened for subclinical endocrinopathies prior to clinical manifestation. Regarding the time interval between manifestation of first and further endocrinopathies, regular and long-term follow-up is warranted. Quality of life and psychosocial status are poor in APD patients and involved relatives. Familial c…

0301 basic medicinePediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismFamilial clusteringClinical manifestationEndocrine System DiseasesAutoimmune Diseases03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeMedicineHumansIn patientStage (cooking)Polyendocrinopathies AutoimmuneSubclinical infectionPatient Care Teambusiness.industrymusculoskeletal neural and ocular physiologyIncidence030104 developmental biologycardiovascular systemQuality of LifeInterdisciplinary CommunicationHigh incidenceMorbiditybusinessPsychosocialcirculatory and respiratory physiologyBest practiceresearch. Clinical endocrinologymetabolism
researchProduct

Differential glutamatergic and GABAergic contributions to the tetrad effects of Δ9-tetrahydrocannabinol revealed by cell-type-specific reconstitution…

2020

Δ9-tetrahydrocannabinol (THC), the major psychoactive ingredient of Cannabis sativa, exerts its actions through the endocannabinoid system by stimulation of the cannabinoid type 1 (CB1) receptor. The widespread distribution of this receptor in different neuronal cell types and the plethora of functions that is modulated by the endocannabinoid system explain the versatility of the effects of THC. However, the cell types involved in the different THC effects are still not fully known. Conditional CB1 receptor knock-out mice were previously used to identify CB1 receptor subpopulations that are "necessary" for the tetrad effects of a high dose of THC: hypothermia, hypolocomotion, catalepsy and …

0301 basic medicinePharmacologyCannabinoid receptormusculoskeletal neural and ocular physiologymedicine.medical_treatmentGlutamate receptorBiologyEndocannabinoid system03 medical and health sciencesCellular and Molecular NeuroscienceGlutamatergic030104 developmental biology0302 clinical medicinenervous systemmental disordersForebrainmedicineGABAergiclipids (amino acids peptides and proteins)CannabinoidReceptorNeurosciencepsychological phenomena and processes030217 neurology & neurosurgeryNeuropharmacology
researchProduct

Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights).

2016

0301 basic medicinePharmacologybusiness.industryApplied psychologyMEDLINEMuscle Proteins03 medical and health sciences030104 developmental biologyThematic mapMyokineDrug DiscoveryMedicineHumansbusinessMuscle SkeletalExerciseCurrent pharmaceutical design
researchProduct

Hsp60 in Skeletal Muscle Fiber Biogenesis and Homeostasis: From Physical Exercise to Skeletal Muscle Pathology

2018

Hsp60 is a molecular chaperone classically described as a mitochondrial protein with multiple roles in health and disease, participating to the maintenance of protein homeostasis. It is well known that skeletal muscle is a complex tissue, rich in proteins, that is, subjected to continuous rearrangements, and this homeostasis is affected by many different types of stimuli and stresses. The regular exercise induces specific histological and biochemical adaptations in skeletal muscle fibers, such as hypertrophy and an increase of mitochondria activity and oxidative capacity. The current literature is lacking in information regarding Hsp60 involvement in skeletal muscle fiber biogenesis and reg…

0301 basic medicinePhysical exerciseInflammationReviewMitochondrionMuscle hypertrophy03 medical and health scienceshomeostasisMedicineskeletal musclelcsh:QH301-705.5diseaseexercisebusiness.industryRegeneration (biology)Skeletal musclehomeostasiGeneral MedicineHsp60Cell biology030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)ageingregenerationmedicine.symptombusinessBiogenesisHomeostasis
researchProduct

Modulation of information processing by AMPA receptor auxiliary subunits

2020

AMPA-type glutamate receptors (AMPARs) are key molecules of neuronal communication in our brain. The discovery of AMPAR auxiliary subunits, such as proteins of the TARP, CKAMP and CNIH families, fundamentally changed our understanding of how AMPAR function is regulated. Auxiliary subunits control almost all aspects of AMPAR function in the brain. They influence AMPAR assembly, composition, structure, trafficking, subcellular localization and gating. This influence has important implications for synapse function. In the present review, we first discuss how auxiliary subunits affect the strength of synapses by modulating number and localization of AMPARs in synapses as well as their glutamate…

0301 basic medicinePhysiology610 MedizinGlutamic AcidGatingAMPA receptorSynaptic TransmissionSynapse03 medical and health sciences0302 clinical medicineHomeostatic plasticity610 Medical sciencesHumansReceptors AMPAReceptorNeuronsNeuronal PlasticityChemistrymusculoskeletal neural and ocular physiologyGlutamate receptor030104 developmental biologyHebbian theorynervous systemSynapsesSynaptic plasticityNeuroscience030217 neurology & neurosurgery
researchProduct